- Trade Name: Taltz (Lilly)
- Indications: Moderate-to-severe plaque psoriasis, active psoriatic arthritis
- Class: Biologic, Interleukin-17 (IL-17) antagonist / interleukin-17 inhibitor, Monoclonal antibody
- Half-life: 13 days
- FDA Approval Date: 03/22/2016
- Clinically important, potentially hazardous interactions with:
Live vaccines - Pregnancy: Insufficient evidence to inform drug-associated risk
- See adverse reactions attributed to class:
Interleukin-17 (IL-17) antagonist / interleukin-17 inhibitor
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE links (above) to see two reviews of ixekizumab in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 11/10/2025
